Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R. Ciotti; Elena Grebenciucova; Brandon P. Moss; Scott D. Newsome

doi:10.1002/ana.25907

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

John R. Ciotti^*, Elena Grebenciucova, Brandon P. Moss, Scott D. Newsome

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	1062-1064
Number of pages	3
Journal	Annals of neurology
Volume	88
Issue number	6
DOIs	https://doi.org/10.1002/ana.25907
State	Published - Dec 2020

ASJC Scopus subject areas

Clinical Neurology
Neurology

Access to Document

10.1002/ana.25907

Cite this

@article{0b83c5033da3463abf71a29bb9ae23dd,

title = "Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era",

author = "Ciotti, {John R.} and Elena Grebenciucova and Moss, {Brandon P.} and Newsome, {Scott D.}",

note = "Funding Information: J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.",

year = "2020",

month = dec,

doi = "10.1002/ana.25907",

language = "English (US)",

volume = "88",

pages = "1062--1064",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

AU - Ciotti, John R.

AU - Grebenciucova, Elena

AU - Moss, Brandon P.

AU - Newsome, Scott D.

N1 - Funding Information: J.R.C.: funded by a Sylvia Lawry Physician Fellowship grant, the National Multiple Sclerosis Society; E.G.: nothing to report; B.P.M.: research funding for investigator‐initiated studies, Roche; site Principal Investigator for studies sponsored by Roche; speaking fees, Genzyme; consulting fees, Roche; owns stock, Pfizer; S.D.N.: scientific advisory boards, Biogen, Genentech, Celgene, Novartis, Greenwich Biosciences, EMD Serono; clinical trial clinical adjudication committee member, BioIncept, Autobahn Therapeutics, medDay Pharmaceuticals; grant/research funding (paid directly to institution), Biogen, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Institute.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85091724611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091724611&partnerID=8YFLogxK

U2 - 10.1002/ana.25907

DO - 10.1002/ana.25907

M3 - Article

C2 - 32951235

AN - SCOPUS:85091724611

SN - 0364-5134

VL - 88

SP - 1062

EP - 1064

JO - Annals of neurology

JF - Annals of neurology

IS - 6

ER -

Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this